Stoichiometry of Monoclonal Antibody Neutralization of T-Cell Line-Adapted Human Immunodeficiency Virus Type 1

ABSTRACT In order to study the stoichiometry of monoclonal antibody (MAb) neutralization of T-cell line-adapted human immunodeficiency virus type 1 (HIV-1) in antibody excess and under equilibrium conditions, we exploited the ability of HIV-1 to generate mixed oligomers when different env genes are coexpressed. By the coexpression of Env glycoproteins that either can or cannot bind a neutralizing MAb in an env transcomplementation assay, virions were generated in which the proportion of MAb binding sites could be regulated. As the proportion of MAb binding sites in Env chimeric virus increased, MAb neutralization gradually increased. Virus neutralization by virion aggregation was minimal, as MAb binding to HIV-1 Env did not interfere with an AMLV Env-mediated infection by HIV-1(AMLV/HIV-1) pseudotypes of CD4− HEK293 cells. MAb neutralization of chimeric virions could be described as a third-order function of the proportion of Env antigen refractory to MAb binding. This scenario is consistent with the Env oligomer constituting the minimal functional unit and neutralization occurring incrementally as each Env oligomer binds MAb. Alternatively, the data could be fit to a sigmoid function. Thus, these data could not exclude the existence of a threshold for neutralization. However, results from MAb neutralization of chimeric virus containing wild-type Env and Env defective in CD4 binding was readily explained by a model of incremental MAb neutralization. In summary, the data indicate that MAb neutralization of T-cell line-adapted HIV-1 is incremental rather than all or none and that each MAb binding an Env oligomer reduces the likelihood of infection.

[1]  C. Wohlfart,et al.  Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms , 1988, Journal of virology.

[2]  A. Trkola,et al.  Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines , 1998, Journal of Virology.

[3]  Q. Sattentau,et al.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer , 1995, The Journal of experimental medicine.

[4]  J. Moore,et al.  HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. , 1995, AIDS.

[5]  J. Hansen,et al.  Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120. , 1998, AIDS research and human retroviruses.

[6]  P. Earl,et al.  Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[8]  A. Osterhaus,et al.  Modulation of primary human immunodeficiency virus type 1 envelope glycoprotein-mediated entry by human antibodies. , 1997, The Journal of general virology.

[9]  R. Dulbecco,et al.  A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus. , 1956, Virology.

[10]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[11]  M. Schutten,et al.  Enhancement of Infectivity of a Non‐Syncytium Inducing HIV‐1 by sCD4 and by Human Antibodies that Neutralize Syncytium Inducing HIV‐1 , 1995, Scandinavian journal of immunology.

[12]  J. Moore,et al.  An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. , 1989, AIDS.

[13]  J. Mascola,et al.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.

[14]  J. Nielsen,et al.  Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. , 1996, Virology.

[15]  Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization , 1997, The Journal of experimental medicine.

[16]  J. Hansen,et al.  Inhibition of HIV type 1 infectivity by coexpression of a wild-type and a defective glycoprotein 120. , 1998, AIDS research and human retroviruses.

[17]  J. Sodroski,et al.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants , 1990, Journal of virology.

[18]  J. Moore,et al.  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1 , 1996, Journal of virology.

[19]  C. Barbas,et al.  Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies , 1998, Journal of Virology.

[20]  R. Rueckert,et al.  Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry. , 1983, Virology.

[21]  L. Bacheler,et al.  HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide. , 1990, AIDS research and human retroviruses.

[22]  B. Chesebro,et al.  Use of a new CD4-positive HeLa cell clone for direct quantitation of infectious human immunodeficiency virus from blood cells of AIDS patients. , 1991, The Journal of infectious diseases.

[23]  P. Earl,et al.  Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein , 1991, Journal of virology.

[24]  J. Sodroski,et al.  Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses , 1996, Journal of virology.

[25]  B. Wahrén,et al.  Neutralizing cross‐reactive and non‐neutralizing monoclonal antibodies to HIV‐1 gp 120 , 1990, AIDS.

[26]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[27]  Q. Sattentau,et al.  Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity , 1998, Journal of Virology.

[28]  Ying Sun,et al.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates , 1995, Journal of virology.

[29]  Claes WOHLFARTt Neutralization of Adenoviruses: Kinetics, Stoichiometry, and Mechanisms , 2022 .

[30]  W. Anderson,et al.  Functional interactions between monomers of the retroviral envelope protein complex , 1997, Journal of virology.

[31]  M. Champe,et al.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 , 1990, Nature.

[32]  E. Wimmer,et al.  Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization , 1983, Journal of virology.

[33]  N. Dimmock,et al.  Quantitative relationships between an influenza virus and neutralizing antibody. , 1987, Virology.

[34]  R. Webster,et al.  Posttranslational oligomerization and cooperative acid activation of mixed influenza hemagglutinin trimers , 1988, The Journal of cell biology.

[35]  J. Sodroski,et al.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.

[36]  B. Mandel Neutralization of poliovirus: a hypothesis to explain the mechanism and the one-hit character of the neutralization reaction. , 1976, Virology.

[37]  R. Compans,et al.  Evidence for Cooperation between Murine Leukemia Virus Env Molecules in Mixed Oligomers , 1998, Journal of Virology.

[38]  P. Earl,et al.  Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain , 1990, Journal of virology.

[39]  E. G. Westaway,et al.  A multi-hit model for the neutralization of animal viruses. , 1978, The Journal of general virology.

[40]  N. Dimmock,et al.  Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. , 1994, The Journal of general virology.